| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 4
| Issue : 1 | Page : 147 |
|
|
Thermoanalytical characterization of clindamycin-loaded intravitreal implants prepared by hot melt extrusion
Lana Tamaddon1, Seyed Abolfazl Mostafavi1, Reza Karkhane2, Mohammad Riazi-Esfahani2, Farid Abedin Dorkoosh3, Morteza Rafiee-Tehrani3
1 Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Ophthalmology, Eye Research Center, Farabi Eye Hospital, Tehran, Iran
3 Department of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Dr. Seyed Abolfazl Mostafavi
Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2277-9175.161563
|
|
|
Background: The aim of the present study was to evaluate a non-destructive fabrication method in for the development of sustained-release poly (L, D-lactic acid)-based biodegradable clindamycin phosphate implants for the treatment of ocular toxoplasmosis.
Materials and Methods: The rod-shaped intravitreal implants with an average length of 5 mm and a diameter of 0.4 mm were evaluated for their physicochemical parameters. Scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier-transform infrared (FTIR), and nuclear magnetic resonance (1H NMR) studies were employed in order to study the characteristics of these formulations.
Results: Drug content uniformity test confirmed the uniformity in different implant batches. Furthermore, the DSC, FTIR, and 1H NMR studies proved that the fabrication process did not have any destructive effects either on the drug or on the polymer structures.
Conclusion: These studies showed that the developed sustained-release implants could be of interest for long-term sustained intraocular delivery of clindamycin, which can provide better patient compliance and also have good potential in terms of industrial feasibility. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
